The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorSecond Xiangya Hospital of Central South University

About this trial

Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. There are no hitherto effective treatments for reducing antipsychotic-induced weight gain. Recently, research suggest that Accelerated dTMS (a-dTMS) which deliver more than one daily TMS session indicates greater efficacy than other TMS treatment. Symptom provocation is believed to improve the clinical responses to TMS. In this study, the investigators, firstly, evaluate the safety and effectiveness of a-dTMS for reducing antipsychotic-induced weight gain and secondly, to establish a predictive model of therapeutic response and to explore the underlying mechanisms of dTMS for reducing antipsychotic-induced weight gain, based on multimodal radiomics and metabolomics approaches.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged between 18-60.

Meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for schizophrenia, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5).

Gaining body weight around 7% after intaking antipsychotics within 2 years.

Participants were on a stable medication regimen at the time of enrollment. ●Written informed consent was obtained from both the participants and their legally authorized guardians.

Disqualifiers

Participants who switch antipsychotic drugs (APDs) or require a dose modification exceeding 25% of the baseline dosage during the study period.

Diagnosed with other mental diseases in accordance with DSM-V.

Comorbid with other severe physiological diseases.

Active suicidal ideation.

Trial design

Design model

Parallel

Treatments tested in this trial

  • dTMS of accelerated intermittent theta burst stimulation, ACC-iTBS

    Device

    The intensity of the stimulator is set at 80% of resting motor threshold (RMT), and the other parameters are set to triplet 50Hz bursts, repeat at 5Hz, 2s seconds on and 8 seconds off, 1800 pulses per session, total duration of 9 minutes and 52 seconds.

  • Sham stimulation

    Device

    The same procedure will be performed in sham coil induced acoustic and scalp sensations similar to those induced by the active coil, but without electromagnetic penetration into the brain and without neural activation.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: a-dTMS stimulationExperimental treatment 1 intervention
Group B: Sham stimulationSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Change in BMI

Unit of measure: BMI in kg/m\^2 (weight in kilograms, height in meters)

Time frame
Change in BMI between baseline and the end of the treatment (day 12) and follow-up (day 42)
2

Change in body weight

Change in body weight (kg) from baseline to Day 12 (end of treatment) and to Day 42 (follow-up), to evaluate the effectiveness of dTMS in reducing antipsychotic-induced weight gain.

Time frame
Change in body weight between baseline and the end of the treatment (day 12) and follow-up (day 42)

Secondary outcomes

1

Change in abdominal and hip circumference

The Change in abdominal and hip circumference absolute values (cm) will be measured at baseline and the end of the treatment (day 12) and follow-up (day 42) to evaluate weight-related treatment responses of dTMS.

Time frame
Change in abdominal and hip circumference between baseline and the end of the treatment (day 12) and follow-up (day 42)
2

Change in Three Factor Eating Questionnaire (TFEQ)

The Food Cravings Questionnaire-Trait (FCQ-T) is a self-reported measures which is a 39-item questionnaire that has nine subscales: intentions and plans to consume food, outcome expectancy of positive reinforcement, outcome expectancy of relief from negative states, anticipated lack of overeating control, preoccupation with food, physiological deficits and responses which may elicit craving, emotions experienced during food craving, external and internal cues that trigger cravings, and guilt.

Time frame
Change in TFEQ between baseline and the end of the treatment (day 12) and follow-up (day 42)
3

Change in Food Cravings Questionnaire-Trait (FCQ-T)

The change of food craving will be evaluated by Food Cravings Questionnaire-Trait (FCQ-T), a self-report multidimensional questionnaire composed of 39 items aimed to investigate food addiction and eating disorders. Total FCQ-T score will be used as a general measure of trait craving; individual FCQ-T scores related to the 9 measured craving dimensions could be useful in identifying and differentiating craving profiles between specific populations.

Time frame
Change in FCQ-T between baseline and the end of the treatment (day 12) and follow-up (day 42)
4

Change in Food Craving Questionnaire State (FCQ-S)

The Food Craving Questionnaire-State (FCQ-S) is a 15-item self-report measure to assess momentary, state-dependent food craving. The instrument consists of five multidimensional subscales: (1) intense desire to eat, (2) anticipation of positive reinforcement from eating, (3) anticipation of relief from negative states and feelings as a result of eating, (4) lack of control over eating, and (5) craving as a physiological state. Respondents rate each item on a 5-point Likert scale ranging from 1 ("strongly disagree") to 5 ("strongly agree"). Total scores are calculated by summing all 15 item responses, yielding a possible range of 15 to 75. Higher total scores indicate more intense current state food cravings.

Time frame
Change in FCQ-S between baseline and the end of the treatment (day 12) and follow-up (day 42)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: